Supplement 18 August 2001

Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Study

The study was coordinated for Scandinavia from the Goteborg University Clinical Research Institute in Go¨teborg and for the United Kingdom and Ireland from the Cardiovascular Studies Unit at Imperial College, London (St Mary’s).

Editorial

Editor’s note
- Eoin O’Brien
Editorial18 Mar 2002 Journal of Human Hypertension

Ascot Committees and List of Investigators

Ascot Committee Members

Ascot Committees and List of Investigators18 Mar 2002 Journal of Human Hypertension

The ASCOT Trial

Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol
- PS Sever
- B Dahlöf
- J Ostergren
The ASCOT Trial18 Mar 2002 Journal of Human Hypertension

Protocols for Sub-study of the ASCOT Trial

An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease
- A Stanton
- D Fitzgerald
- S Thom
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics
- P Uusimaa
- H Tokola
- K Peuhkurinen
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Cardiovascular risk factors in a cohort of 30 000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
- JN Chapman
- P Kirby
- NR Poulter
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo
- MS Nieminen
- J Viikari
- H Vanhanen
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Evaluation of cardiovascular risk equations using the ASCOT cohort
- S Wilson
- D Collier
- M Caulfield
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Health-related quality of life and psychological factors in treatment of hypertension
- J Julkunen
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment
- CGC Spencer
- DG Beevers
- GYH Lip
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects
- L Oikarinen
- M Viitasalo
- MS Nieminen
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients
- E O’Brien
- GT McInnes
- FM Nichol
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
- B Jönsson
- M Buxton
- for the ASCOT Health Economics Working Group
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease
- DJ Collier
- L Bernardi
- P Sleight
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group
- PL Kirby
- MC Caulfield
- GS Feder
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Do hypertensive patients’ beliefs about their illness and treatment influence medication adherence and quality of life?
- R Horne
- J Clatworthy
- J Weinman
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
The Conduit Artery Functional Endpoint (CAFE) study in ASCOT
- B Williams
- M O’Rourke
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Left ventricular hypertrophy and silent ischaemia: a pilot study to examine the relationship in hypertensive patients
- E O’Brien
- C Gribbin
- S Lyons
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Microalbuminuria in type 2 diabetic hypertensive patients in ASCOT
- JP O’Hare
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Non-specific effects of inclusion in a clinical trial: information from ASCOT
- S Thom
- A Whitehouse
- N Poulter
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
The suitability of an automated blood pressure measuring device—the Omron HEM-705CP—in a large multicentre study: the ASCOT study
- H O’Neill
- E O’Brien
- K Hedditch
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Ethnic variations in response to a statin (EVIREST)
- NR Poulter
- M Caulfield
- G Feder
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
The effects of cardiac events on quality of life and indirect costs
- B Jönsson
- M Buxton
- for the ASCOT Health Economic Working Group
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension
Microvolt T wave alternans in patients with hypertension and left ventricular hypertrophy
- D Francis
- R Lane
- NS Peters
Protocol for Sub-Study of the ASCOT Trial18 Mar 2002 Journal of Human Hypertension

Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Study

Editorial

Editor’s note

Ascot Committees and List of Investigators

Ascot Committee Members

The ASCOT Trial

Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol

Protocols for Sub-study of the ASCOT Trial

An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease

Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics

Cardiovascular risk factors in a cohort of 30 000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo

Evaluation of cardiovascular risk equations using the ASCOT cohort

Health-related quality of life and psychological factors in treatment of hypertension

Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment

Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects

Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients

Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease

Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group

Do hypertensive patients’ beliefs about their illness and treatment influence medication adherence and quality of life?

The Conduit Artery Functional Endpoint (CAFE) study in ASCOT

Left ventricular hypertrophy and silent ischaemia: a pilot study to examine the relationship in hypertensive patients

Microalbuminuria in type 2 diabetic hypertensive patients in ASCOT

Non-specific effects of inclusion in a clinical trial: information from ASCOT

The suitability of an automated blood pressure measuring device—the Omron HEM-705CP—in a large multicentre study: the ASCOT study

Ethnic variations in response to a statin (EVIREST)

The effects of cardiac events on quality of life and indirect costs

Microvolt T wave alternans in patients with hypertension and left ventricular hypertrophy

Search

Quick links